KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查 入排置信度 0.95

Meaningful Symptomatic Change in Patients With Myelofibrosis From the SIMPLIFY Studies.

Stacie Hudgens, Srdan Verstovsek, Lysbeth Floden, Claire N Harrison, Jeanne Palmer, Vikas Gupta, Donal McLornan, Mary Frances McMullin, Jean-Jacques Kiladjian, Lynda Foltz, Uwe Platzbecker, Maria Laura Fox, Adam J Mead, David M Ross, Stephen T Oh, Andrew A Perkins, Michael F Leahy, Samineh Deheshi, Rafe Donahue, Barbara J Klencke, Ruben A Mesa

Value Health 27(5) 607-613

PMID38311180
PMCID-
DOI10.1016/j.jval.2024.01.014
发表日期2024-02-04
入排依据:The study is a randomized Phase III trial with a drug intervention and original results, but it does not have a primary or key secondary time-to-event efficacy endpoint. The focus is on establishing a meaningful symptom change threshold, which falls under quality-of-life analysis, not the required time-to-event outcome for inclusion.
摘要

摘要

OBJECTIVES: Patients with myelofibrosis develop symptoms due to bone marrow fibrosis, systemic inflammation, and/or organomegaly. Alleviating symptoms improves overall quality of life. Clinical trials have historically defined symptom response as a reduction of at least 50% in Total Symptom Score at week 24 compared with baseline. Whether 50% constitutes a meaningful benefit has not been established. This study determined the meaningful change threshold (MCT) for 2 momelotinib phase III trials, SIMPLIFY-1 and SIMPLIFY-2. METHODS: The absolute and percentage MCT was determined using anchor-based methods applied to the modified Myeloproliferative Neoplasm Symptom Assessment Form v2.0 and Patient Global Impression of Change. MCTs were applied retrospectively to determine responder rates. Generalized estimating equations estimated the treatment-related difference in likelihood of improvement. RESULTS: In SIMPLIFY-1, a Janus kinase inhibitor-naive population, the MCT was 8 points. In SIMPLIFY-2, a previously Janus kinase inhibitor-treated population, the MCT was 6 points. A 32% MCT was determined in both studies, showing that the historic 50% reduction threshold may be a conservative choice. In SIMPLIFY-1, a similar proportion of patients achieved responder status with 24 weeks of momelotinib or ruxolitinib therapy based on the absolute MCT (39% vs 41%, respectively). In SIMPLIFY-2, a significantly greater proportion of patients treated with momelotinib achieved responder states compared with best available therapy based on absolute and percent change MCTs. CONCLUSIONS: This study demonstrates that momelotinib provided clinically meaningful symptom benefit for patients with myelofibrosis and provides insight into the appropriateness of the symptom change threshold used in historical studies.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。